A Favorable Response to Cisplatin, Pemetrexed and Bevacizumab in Two Cases of Invasive Mucinous Adenocarcinoma Formerly Known as Pneumonic-type Mucinous Bronchioloalveolar Carcinoma

DOI Web Site PubMed 1 Citations 9 References Open Access
  • Yamakawa Hideaki
    Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan Department of Respiratory Medicine, Jikei University School of Medicine, Japan
  • Takayanagi Noboru
    Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan
  • Ishiguro Takashi
    Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan
  • Kagiyama Naho
    Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan
  • Shimizu Yoshihiko
    Department of Diagnostic Pathology, Saitama Cardiovascular and Respiratory Center, Japan
  • Sugita Yutaka
    Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan

Search this article

Description

The leading subtype of lung cancer, adenocarcinoma, received a new classification in 2011 when multifocal, pneumonic-type mucinous tumors, formerly called mucinous bronchioloalveolar carcinomas, were reclassified as "invasive mucinous adenocarcinomas." These tumors appear to be less sensitive to chemotherapy than other non-small cell lung cancers. We herein report two cases of invasive mucinous adenocarcinoma that showed a dramatic radiologic response to combination therapy with cisplatin, pemetrexed and bevacizumab. Recent data suggest that the use of paclitaxel-based chemotherapy is an acceptable therapeutic strategy in cases of invasive mucinous adenocarcinoma. The cases reported here and preclinical findings suggest the therapeutic efficacy of cisplatin, pemetrexed and bevacizumab in treating such tumors.<br>

Journal

  • Internal Medicine

    Internal Medicine 52 (24), 2781-2784, 2013

    The Japanese Society of Internal Medicine

Citations (1)*help

See more

References(9)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top